PubRank

M E Moynahan

Author PubWeight™ 17.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. Genes Dev 1998 4.68
2 Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001 3.06
3 Double-strand breaks and tumorigenesis. Trends Cell Biol 2001 2.53
4 Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998 1.68
5 Partial characterization of a growth-inhibiting protein in 3T3 cell plasma membranes. Exp Cell Res 1982 1.00
6 Targeted transgenesis. Proc Natl Acad Sci U S A 1996 0.99
7 Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996 0.92
8 Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 2001 0.90
9 Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 1995 0.81
10 Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer. Semin Oncol 1997 0.79
11 Homologous recombination between heterologs during repair of a double-strand break. Suppression of translocations in normal cells. Ann N Y Acad Sci 1999 0.79
12 Binding, internalization, and degradation of [125I]insulin by cultured bovine aortic endothelial cells: effects of serotonin. In Vitro 1983 0.75
13 Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 1999 0.75